Inex Completes Bought Deal of Common Shares

Inex Pharmaceuticals Corporation, a biopharmaceutical company that utilizes novel therapeutic compounds and proprietary drug delivery systems to commercialize improved therapies for the treatment of cancer, completed its $43 million bought deal of common shares through an underwriting syndicate led by BMO Nesbitt Burns Inc., and included Raymond James Financial, Inc., RBC Dominion Securities Inc., Yorkton Securities Inc. and Dlouhy Merchant Group Inc. The deal closed on December 13, 2001.

Lang Michener's Vancouver office acted for Inex, with a team that included Leo Raffin, Charlotte Olsen and Barbara Snyder; with assistance from Richard Bowry of Appleby Spurling & Kempe on Bermuda law matters; Traci Juman of the law office of Garth St. E. W. Patterson on Barbados law matters; Chris Barry and Randy Price of Dorsey & Whitney LLP in Toronto and Seattle on U.S. law matters; and Eugenia Garrett-Wackowski and Joseph Snyder of Townsend and Townsend and Crew LLP in San Francisco on patent matters. Campney & Murphy in Vancouver acted for the underwriters, with a team that included Iain Mant, Joseph Garcia and Bruce Tattrie.